Do pathogenic LRRK2 mutations amplify volume-sensing signals or just elevate baseline kinase activity?

Title: `G2019S raises the LRRK2 kinase floor more than the swelling gain`

Mechanism: G2019S may primarily increase constitutive catalytic output, producing higher baseline pRab10/pRab12 without materially changing the slope of the lysosomal volume-response curve. In this model, swelling still activates the same upstream lysosomal recruitment/activation circuit, but mutant cells start from a higher baseline rather than showing stronger fold-amplification.

Target gene/protein/pathway: `LRRK2` kinase domain, `RAB10`, `RAB12`, lysosomal stress signaling

Supporting evidence: G2019S often shows only modest endogenous pRab10 elevation compared with stronger ROC-COR mutants such as R1441G (PMID: `34125248`). G2019S carriers do show elevated phospho-Rab biomarkers in some contexts, including pRab12 in PBMCs (PMID: `39705401`). Membrane recruitment itself is sufficient to drive Rab phosphorylation, consistent with a recruitment-triggered pathway onto which G2019S could add a higher basal catalytic set-point (PMID: `35580815`).

Falsifiable experiment: Use isogenic WT and G2019S human iPSC-derived microglia and macrophages. Apply graded lysosomal swelling stimuli (`apilimod`, sucrose loading, low-dose chloroquine), then quantify baseline, EC50, maximal response, and fold-change for `pT73-RAB10`, `pS106-RAB12`, and `pS1292-LRRK2`. This hypothesis is supported if G2019S shifts baseline upward with little change in EC50 or maximal fold induction.

Confidence: `0.73`

Title: `The true mutant amplification may be in LYTL/JIP4 remodeling, not bulk pRab10 abundance`

Mechanism: G2019S may not dramatically amplify total Rab10 phosphorylation during swelling, but may disproportionately enhance downstream lysosomal tubulation/sorting (`LYTL`) through `JIP4`, `RAB10`, and `RAB35`. That would make the disease-relevant phenotype membrane remodeling and cargo export rather than simple phospho-signal height.

Target gene/protein/pathway: `JIP4`, `RAB10`, `RAB35`, `LRRK2`, LYTL pathway

Supporting evidence: LRRK2 drives lysosomal tubulation and vesicle sorting through JIP4 and Rab phosphorylation (PMID: `33177079`). Forced membrane localization of LRRK2 is sufficient to trigger `RAB10`, `RAB12`, and `JIP4` signaling, and pathogenic mutants show additive effects with membrane recruitment (PMID: `35580815`).

Falsifiable experiment: In WT versus G2019S knock-in microglia, induce lysosomal swelling and perform live-cell imaging of `LAMP1`, `JIP4`, `RAB10`, and tubule formation. Measure tubule number, duration, vesicle release, and dependence on `MLi-2` or `JIP4` knockdown. This hypothesis is supported if G2019S selectively increases LYTL kinetics/output more than it increases bulk pRab10.

Confidence: `0.69`

Title: `Phosphatase buffering makes G2019S look like a baseline defect in some cell types`

Mechanism: Whether G2019S appears as “higher baseline” versus “signal amplification” may depend on phospho-Rab turnover, especially via `PPM1H` and possibly `PPM1M`. Fast dephosphorylation of `pRab10` could compress dynamic range, masking true activation, while `pRab12` remains more sensitive in some compartments/cell types.

Target gene/protein/pathway: `PPM1H`, `PPM1M`, `RAB10`, `RAB12`, `LRRK2`

Supporting evidence: `PPM1H` is a key Rab phosphatase that reverses LRRK2-dependent Rab phosphorylation (PMID: `31663853`), and its localization strongly affects Rab10 dephosphorylation (PMID: `37889931`). Recent human PBMC data suggest `pRAB12` may outperform `pRAB10` as a G2019S biomarker (PMID: `39705401`).

Falsifiable experiment: In isogenic WT/G2019S microglia, perturb `PPM1H` or `PPM1M` by CRISPRi/overexpression, then run swelling-response curves for `pRab10` and `pRab12`. This hypothesis is supported if phosphatase suppression unmasks a stronger mutant-dependent dynamic response, especially for `Rab10`.

Confidence: `0.76`

Title: `G2019S preferentially amplifies volume-sensing in professional phagocytes and microglia`

Mechanism: The strongest mutant-dependent amplification may occur in cells with high endogenous `LRRK2` and constitutive endolysosomal load, especially macrophages and microglia, not neurons. In these cells, mutant LRRK2 could convert routine cargo-induced lysosomal swelling into exaggerated `Rab10`-dependent trafficking and inflammatory signaling.

Target gene/protein/pathway: `LRRK2`, `RAB10`, macropinocytosis/endolysosomal pathway, microglia/macrophages

Supporting evidence: LRRK2 and Rab10 are highly active in phagocytes and regulate macropinocytosis/signaling endosomes (PMID: `32853409`). Lysosomal stress and fibrillar α-synuclein drive LRRK2-Rab10 signaling and extracellular release in macrophage-lineage cells and microglia (PMID: `38313055`).

Falsifiable experiment: Compare WT and G2019S iPSC-derived microglia, peripheral monocyte-derived macrophages, and dopaminergic neurons under identical swelling/cargo-loading paradigms. Readouts: `pRab10`, `pRab12`, lysosome size, cytokines, and α-syn release. This hypothesis is supported if amplification is strong in microglia/macrophages but weak or absent in neurons.

Confidence: `0.81`

Title: `Pathogenic output is better captured by substrate switching toward Rab12 during chronic lysosomal stress`

Mechanism: G2019S may alter substrate preference under chronic lysosomal stress, with `RAB12` becoming a more informative readout than `RAB10`. If so, debate framing around Rab10 alone may miss genuine mutant amplification in lysosome-associated signaling.

Target gene/protein/pathway: `RAB12`, `RAB10`, `LRRK2`, granulovacuolar/lysosomal pathway

Supporting evidence: G2019S carrier PBMCs show elevated `pSer106-RAB12` (PMID: `39705401`). In human neurodegenerative brain tissue, both `pRAB12` and `pRAB10` accumulate in lysosome-like granulovacuolar structures, including in G2019S-linked disease (PMID: `41128923`).

Falsifiable experiment: Perform phosphoproteomic time-course profiling in WT and G2019S microglia after acute versus chronic lysosomal swelling. Quantify `pRab10`, `pRab12`, localization to `LAMP1`/GVB-like compartments, and phosphatase sensitivity. This hypothesis is supported if chronic stress selectively increases mutant `pRab12` or shifts the `pRab12:pRab10` ratio.

Confidence: `0.71`

Title: `Mutant LRRK2 turns lysosomal swelling into a feed-forward α-synuclein propagation loop`

Mechanism: Even if G2019S only modestly raises baseline kinase activity, that may be enough to amplify a thresholded loop in which swollen lysosomes recruit LRRK2, phosphorylate `RAB10`, promote vesicle sorting/exosome release, and increase extracellular pathogenic α-synuclein. Therapeutically, partial LRRK2 inhibition could break this loop without fully abolishing basal lysosomal surveillance.

Target gene/protein/pathway: `LRRK2-RAB10-JIP4`, lysosomal exocytosis/exosome pathway, α-synuclein handling

Supporting evidence: Lysosomal stress promotes α-synuclein release through the LRRK2-Rab10 pathway in macrophage-lineage cells and microglia (PMID: `38313055`). LRRK2-dependent lysosomal tubulation/sorting provides a plausible export mechanism downstream of Rab phosphorylation (PMID: `33177079`).

Falsifiable experiment: Load WT and G2019S microglia with α-syn PFFs, then induce controlled lysosomal swelling. Measure exosomal α-syn release, cathepsin release, neuron-to-microglia propagation, and rescue with partial versus full LRRK2 inhibition or `RAB10/JIP4` suppression. This hypothesis is supported if G2019S disproportionately increases cargo release/propagation relative to its effect on baseline pRab10.

Confidence: `0.84`

Most actionable discriminator: run stimulus-response curves plus downstream trafficking phenotypes in isogenic WT vs G2019S microglia/macrophages, measuring both baseline and delta for `pRab10`, `pRab12`, `JIP4/LYTL`, and α-syn release. That cleanly separates “higher floor” from “true amplification.”

Skeptical Read

The main weakness across all six is the same: most cited evidence shows that mutant `LRRK2` can elevate phospho-Rab output or alter lysosomal remodeling, but it does not cleanly separate `baseline offset` from `stimulus gain`. Much of the literature uses overexpression, artificial membrane targeting, `LLOME` or lysosomotropic stress, PBMCs, or macrophage-like cells. Those systems are useful for mechanism discovery, but they are not decisive for the specific question “does G2019S amplify volume sensing, or just raise the floor?”

`G2019S raises the kinase floor more than the swelling gain`

Weak evidence: this is plausible, but the support is indirect. PMID [34125248](https://pubmed.ncbi.nlm.nih.gov/34125248/) shows weak endogenous `pRab10` elevation for G2019S in neutrophils relative to stronger `R1441G`, but neutrophils are not lysosomal-swelling models. PMID [35580815](https://pubmed.ncbi.nlm.nih.gov/35580815/) shows membrane recruitment is sufficient for signaling, but that is an engineered recruitment system, not physiological volume sensing.
Alternative mechanisms: G2019S could increase dwell time on lysosomal membranes, alter substrate access, or change phosphatase balance rather than simply shifting basal catalytic output.
Translational risk: if you conclude “just a higher floor,” you may miss cell-state-dependent amplification that matters in microglia but not blood cells.
Falsifier: fit full dose-response curves in isogenic endogenous-expression WT vs G2019S cells and compare baseline, Hill slope, `EC50`, and `Emax`. This hypothesis fails if G2019S significantly increases slope or `Emax` after baseline normalization.

`Amplification is in LYTL/JIP4 remodeling, not bulk pRab10`

Weak evidence: PMID [33177079](https://pubmed.ncbi.nlm.nih.gov/33177079/) and [35580815](https://pubmed.ncbi.nlm.nih.gov/35580815/) strongly support `LRRK2`-dependent `JIP4` recruitment and tubulation, but much of that evidence comes from overexpression and acute lysosomal damage paradigms. That is not the same as endogenous mutant-specific amplification during physiological swelling.
Alternative mechanisms: more tubules could reflect altered lysosome injury/repair, microtubule organization, or cargo burden, not selective amplification downstream of volume sensing.
Translational risk: LYTL may be a visually striking cell-biology phenotype without being the disease-relevant bottleneck in human PD tissue.
Falsifier: quantify LYTL kinetics at endogenous `LRRK2` levels after matched swelling in WT and G2019S, then normalize for lysosome number/size and total `pRab10`. This hypothesis fails if LYTL output scales proportionally with phospho-Rab signal and shows no mutant-specific excess.

`Phosphatase buffering makes G2019S look like a baseline defect`

Weak evidence: `PPM1H` clearly opposes LRRK2-Rab phosphorylation in PMID [31663853](https://elifesciences.org/articles/50416) and its localization shapes substrate handling in PMID [37889931](https://pubmed.ncbi.nlm.nih.gov/37889931/). But invoking phosphatase buffering here is still speculative unless turnover is measured in the exact swelling context. `PPM1M` is also now relevant for `Rab12` and complicates the simpler `PPM1H` story (PMID [40690364](https://pubmed.ncbi.nlm.nih.gov/40690364/)).
Alternative mechanisms: apparent compression of dynamic range may come from antibody nonlinearity, compartment mixing, substrate relocalization, or unequal total Rab pools rather than phosphatase buffering.
Translational risk: phosphatase modulation may look elegant mechanistically but could be hard to drug safely, and blood biomarker behavior may not mirror brain endolysosomal compartments.
Falsifier: perform pulse-chase inhibition of `LRRK2` during and after swelling, with compartment-resolved phospho-Rab decay kinetics in WT/G2019S and phosphatase perturbation. This hypothesis fails if turnover rates are unchanged and only production rates differ.

`Amplification is strongest in phagocytes/microglia`

Weak evidence: PMID [32853409](https://pubmed.ncbi.nlm.nih.gov/32853409/) and [38313055](https://pubmed.ncbi.nlm.nih.gov/38313055/) support strong `LRRK2-Rab10` signaling in phagocytes and microglia-like cells. But that mainly shows these cells are a permissive context, not that G2019S specifically amplifies volume sensing there.
Alternative mechanisms: higher apparent amplification could simply reflect higher endogenous `LRRK2`, more macropinocytosis, or heavier lysosomal cargo flux, not a mutation-specific gain mechanism.
Translational risk: PD vulnerability is neuronal; a microglia-dominant phenotype may be real but still not explain dopaminergic degeneration or therapeutic response in patients.
Falsifier: compare WT and G2019S across matched cell types with equalized `LRRK2` abundance and standardized cargo load. This hypothesis fails if mutation effects track `LRRK2` expression level rather than cell identity.

`Pathogenic output is better captured by Rab12 than Rab10 during chronic stress`

Weak evidence: PMID [39705401](https://pubmed.ncbi.nlm.nih.gov/39705401/) makes `pRab12` a credible blood biomarker in G2019S carriers, and PMID [41128923](https://pubmed.ncbi.nlm.nih.gov/41128923/) links `pRab12` to lysosome-like pathology in human brain. But neither proves substrate switching during chronic swelling in living disease-relevant cells.
Alternative mechanisms: `pRab12` may simply be easier to detect because of weaker phosphatase opposition, different compartment retention, or better assay behavior, not because the mutant truly switches substrates.
Translational risk: biomarker superiority in PBMCs may not mean mechanistic superiority in brain. Chronic stress paradigms are also vulnerable to secondary transcriptional and lysosomal adaptation effects.
Falsifier: use time-resolved phosphoproteomics plus absolute immunoblot calibration for `pRab10` and `pRab12` under acute and chronic stress, with phosphatase controls. This hypothesis fails if the `pRab12:pRab10` ratio does not shift in a mutation-dependent way once turnover and localization are controlled.

`Mutant LRRK2 creates a feed-forward α-syn propagation loop`

Weak evidence: PMID [38313055](https://pubmed.ncbi.nlm.nih.gov/38313055/) supports an `LRRK2-Rab10`-dependent α-syn release pathway in macrophage-lineage cells and microglia. But that is still several inferential steps away from human PD propagation, and it does not isolate G2019S-specific gain versus a generic lysosomal-stress pathway.
Alternative mechanisms: α-syn release may reflect generalized lysosomal overload, exosome stress responses, inflammasome-linked secretion, or cell injury, with `LRRK2-Rab10` acting permissively rather than as the core amplifier.
Translational risk: blocking this loop in vitro may not reduce spread in vivo, and partial kinase inhibition may have nonlinear effects on host defense or lysosomal homeostasis.
Falsifier: test WT vs G2019S in co-culture or in vivo propagation models with matched uptake, viability, and lysosomal injury metrics. This hypothesis fails if G2019S does not increase seeded spread once nonspecific stress-induced release is controlled.

Bottom line

The most likely overreach in the theorist set is treating related findings as if they already distinguish `baseline`, `gain`, `substrate choice`, and `downstream remodeling`. They mostly do not. The cleanest discriminator is still a quantitative endogenous dose-response design in isogenic cells, with explicit separation of:
`baseline`, `delta over baseline`, `EC50`, `Emax`, phospho-Rab turnover, and downstream LYTL/α-syn outputs.

Sources
PMID [34125248](https://pubmed.ncbi.nlm.nih.gov/34125248/), [35580815](https://pubmed.ncbi.nlm.nih.gov/35580815/), [33177079](https://pubmed.ncbi.nlm.nih.gov/33177079/), [31663853](https://elifesciences.org/articles/50416), [37889931](https://pubmed.ncbi.nlm.nih.gov/37889931/), [32853409](https://pubmed.ncbi.nlm.nih.gov/32853409/), [38313055](https://pubmed.ncbi.nlm.nih.gov/38313055/), [39705401](https://pubmed.ncbi.nlm.nih.gov/39705401/), [41128923](https://pubmed.ncbi.nlm.nih.gov/41128923/), [40690364](https://pubmed.ncbi.nlm.nih.gov/40690364/).

As of April 24, 2026, the hypotheses that most credibly survive are:

#1 Higher baseline kinase activity more than higher swelling gain

#4 Amplification is context-dependent and strongest in microglia/macrophages

#5 `pRab12` may be the better translational biomarker under chronic lysosomal stress

#6 A downstream `LRRK2-Rab10/JIP4` lysosomal stress to α-syn release loop is plausible

#2 LYTL/JIP4 remodeling is a useful mechanistic phenotype, but not yet a primary therapeutic thesis

#3 phosphatase buffering survives as an assay-interpretation modifier, not as a realistic near-term drug program.

The key point is that the druggable node is still LRRK2 kinase, not Rab12, JIP4, or PPM1H/M today. The main open question is not “what to drug?” but “which biology best predicts benefit, in which cell type, and with which biomarkers?”

Priority Assessment

| Idea | Feasibility | Druggability | Biomarker readiness | Trial readiness |
|---|---|---:|---:|---:|
| #1 Baseline floor > gain | High | High via LRRK2 inhibitors | High | High |
| #4 Microglia/phagocyte-selective amplification | High | Indirectly high | Medium-High | Medium |
| #5 Rab12 as chronic-stress biomarker | Medium-High | Low as target, high as biomarker | High exploratory | Medium |
| #6 α-syn feed-forward loop | Medium | High via LRRK2, low via downstream nodes | Medium | Medium-Low |
| #2 LYTL/JIP4 remodeling | Medium | Low-Medium | Medium | Low |

Per Surviving Idea

1. G2019S mainly raises the activity floor
This is the strongest and most development-relevant interpretation. It fits the neutrophil data where R1441G is much stronger than G2019S for endogenous pRab10, and it is consistent with the idea that membrane recruitment is the main activation event while G2019S adds modest catalytic bias rather than a huge gain boost. Sources: [PMID 34125248](https://pubmed.ncbi.nlm.nih.gov/34125248/), [PMID 35580815](https://pubmed.ncbi.nlm.nih.gov/35580815/).

Druggability: high, because it points directly to partial LRRK2 kinase inhibition, which is already clinically actionable.

Biomarkers/model systems: use isogenic WT vs G2019S iPSC-microglia and monocyte-derived macrophages with graded swelling paradigms; primary readouts should be `pT73-Rab10`, `pS106-Rab12`, `pS1292-LRRK2`, urine BMP, and PBMC phospho-Rab. Avoid overexpression and avoid relying on LLOME alone.

Safety: best-understood among all ideas because it leverages the existing LRRK2 inhibitor path. Main known risks remain lung type II pneumocyte vacuolation, renal morphology, and immune/host-defense effects, though preclinical lung/kidney changes were reported as reversible and early BIIB122 studies were generally tolerable. Sources: [PMID 32321864](https://pubmed.ncbi.nlm.nih.gov/32321864/), [PMID 29307545](https://pubmed.ncbi.nlm.nih.gov/29307545/).

Timeline/cost: 12-18 months, $1.5M-$3M for a decisive preclinical package; if positive, it can feed directly into ongoing LRRK2 clinical biomarker work rather than needing a new drug program.

4. Amplification is strongest in microglia/macrophages
This is very plausible biologically and matters for disease mechanism, even if it may not fully explain neuronal vulnerability. Phagocytes clearly have stronger endogenous `LRRK2-Rab10` biology and more relevant lysosomal cargo handling. Sources: [PMID 32853409](https://pubmed.ncbi.nlm.nih.gov/32853409/), [PMID 38313055](https://pubmed.ncbi.nlm.nih.gov/38313055/).

Druggability: still via LRRK2 inhibition, not via “microglia-specific volume sensing” per se.

Biomarkers/model systems: strongest systems are iPSC-microglia, primary monocyte/macrophage models, and co-cultures with neurons for cargo-transfer effects. This is more informative than dopaminergic monoculture for this specific hypothesis.

Safety: favorable from a translational logic standpoint because microglia/macrophages are likely where on-target pharmacology will be most visible, but that also raises innate immune suppression / altered trafficking concerns if inhibition is too deep.

Timeline/cost: 18-24 months, $3M-$5M for a solid cell-type comparison package with live imaging, cytokines, cargo trafficking, and pharmacology. Good mechanistic program; not by itself a new IND path.

5. Rab12 may outperform Rab10 as the translational readout
This is the best biomarker-facing idea. Human PBMC data now support `pS106-Rab12` elevation in G2019S carriers, and recent brain pathology data show `pRab12` accumulation in lysosome-like structures across synuclein/tau disease contexts, including G2019S-linked disease. Sources: [PMID 39705401](https://pubmed.ncbi.nlm.nih.gov/39705401/), [PMID 41128923](https://pubmed.ncbi.nlm.nih.gov/41128923/), [PMID 37889931](https://pubmed.ncbi.nlm.nih.gov/37889931/), [PMID 40690364](https://pubmed.ncbi.nlm.nih.gov/40690364/).

Druggability: low as a direct target. `Rab12` is much more useful as a pharmacodynamic / enrichment biomarker than as a therapeutic node.

Biomarkers/model systems: PBMC assay development is already realistic. Best package is paired PBMC + iPSC-microglia time-course with acute and chronic stress, measuring `pRab12:pRab10` ratio and inhibitor response.

Safety: biomarker-only work is low risk. Therapeutically targeting phosphatases like `PPM1M` or `PPM1H` would be much riskier because these enzymes sit in broad trafficking/ciliogenesis biology.

Timeline/cost: 9-15 months, $1M-$2.5M for assay qualification and translational bridging. This is the fastest path to something clinically useful.

6. Feed-forward α-syn release loop
This is disease-relevant and interesting, but still one inferential step farther from a practical development decision. The macrophage/microglia data support a lysosomal overload to `LRRK2-Rab10` to exosomal α-syn release axis. Source: [PMID 38313055](https://pubmed.ncbi.nlm.nih.gov/38313055/).

Druggability: again strongest at LRRK2, not at exosome biology or JIP4 directly.

Biomarkers/model systems: use PFF-loaded microglia, conditioned media transfer, exosome fractionation, extracellular α-syn species, and matched viability/lysosomal injury controls. This is a strong secondary package after the baseline-vs-gain question is settled.

Safety: biggest translational risk is that suppressing this loop may also alter normal vesicle trafficking and innate immune handling. The biology is compelling, but not yet specific enough to define a new target.

Timeline/cost: 18-30 months, $4M-$8M for a serious preclinical package including co-culture and one in vivo propagation model.

2. LYTL/JIP4 remodeling
Useful as a mechanistic discriminator, not a primary program. LYTL is real, but the evidence base still leans on acute injury paradigms and imaging-heavy phenotypes. Sources: [PMID 33177079](https://pubmed.ncbi.nlm.nih.gov/33177079/), [PMID 35580815](https://pubmed.ncbi.nlm.nih.gov/35580815/).

Druggability: weak to moderate. `JIP4` is not an attractive conventional small-molecule target today, and disrupting lysosomal tubulation broadly could create toxicity.

Biomarkers/model systems: live-cell imaging of `LAMP1`, `JIP4`, tubule number/duration, and vesicle release is worthwhile as a secondary mechanistic endpoint.

Safety: higher uncertainty than kinase inhibition because this pathway is less clinically de-risked.

Timeline/cost: 12-24 months, $2M-$4M. Good for target validation, poor for standalone translation.

What I would actually advance
The best near-term program is:

Run the endogenous dose-response study in isogenic WT/G2019S microglia and macrophages.

Make `pRab12` and `pRab10` paired biomarkers, not competitors.

Treat LYTL and α-syn release as downstream discriminators, not primary theses.

Keep the therapeutic strategy centered on partial LRRK2 inhibition.

That is the only path here that is both mechanistically clean and developmentally realistic. It also fits the current clinical landscape: BIIB122 remains in active Phase 2 development, with LUMA enrolled and a Phase 2a LRRK2-PD biomarker study (NCT06602193) recruiting/ongoing as of February 18, 2026. Sources: [ClinicalTrials.gov NCT06602193](https://www.clinicaltrials.gov/study/NCT06602193), [Denali 2026 milestones](https://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-key-anticipated-milestones-and).

If you want, I can turn this into a strict go/no-go matrix with scores for druggability, assayability, patient-selection value, and estimated probability of clinical translation.